Key result
WATCHMAN device achieves 100% effective LAAC in Japanese patients with NVAF.
Why the study?
The study was conducted to confirm the safety and efficacy of the WATCHMAN left atrial appendage closure device for stroke prevention in patients with nonvalvular atrial fibrillation in Japan.
Does left atrial appendage closure with the WATCHMAN device safely and effectively prevent stroke in Japanese patients with nonvalvular atrial fibrillation?
Does left atrial appendage closure with the WATCHMAN device safely and effectively prevent stroke in Japanese patients with nonvalvular atrial fibrillation?
The WATCHMAN LAAC device is a safe and effective nonpharmacological alternative for stroke risk reduction in Japanese patients with NVAF who are unsuitable for lifelong anticoagulation.
Answers are grounded in this paper and cite their sources.
Supports WATCHMAN LAAC feasibility in Japanese NVAF patients; leaves open need for randomized efficacy data versus anticoagulation.
BACKGROUND: The SALUTE trial was a prospective, multicenter, single-arm trial to confirm the safety and efficacy of the WATCHMAN left atrial appendage closure (LAAC) device for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in Japan. METHODS AND All 42 subjects in the intention to treat (ITT) cohort underwent successful implantation of the LAAC device without any serious complications, achieving the prespecified performance goal. The effective LAAC rate was maintained at 100% from 45 days to 12 months post-implant, achieving the prespecified performance goal. During follow-up, 1 subject died of heart failure, and 3 had ischemic strokes, but there were no cases of hemorrhagic stroke or systemic embolism. All events were adjudicated as unrelated to the WATCHMAN device/procedure by the independent Clinical Events Committee. All 3 ischemic strokes were classified as nondisabling based on no change in the modified Rankin scale score. CONCLUSIONS: Final results of the SALUTE trial demonstrated that the WATCHMAN LAAC device is an effective and safe alternative nonpharmacological therapy for stroke risk reduction in Japanese NVAF patients who are not optimal candidates for lifelong anticoagulation. (Trial Registration: clinicaltrials.gov Identifier NCT03033134).
No takes yet. Share an insight, caveat, or question.
Aonuma et al. (2020) studied Nonvalvular atrial fibrillation (NVAF) (n=42). WATCHMAN left atrial appendage closure (LAAC) device was evaluated on Effective LAAC rate (peri-device flow ≤5 mm) at 45 days. The WATCHMAN left atrial appendage closure device achieved a 100% effective closure rate at 45 days to 12 months in Japanese patients with nonvalvular atrial fibrillation, exceeding the 94.0% performance goal.
Synapse has enriched 10 related papers. Consider them for comparative context: